Apogee Therapeutics' Investigational Atopic Dermatitis Potential Shows Strong Tolerability, Extended Half-Life in Early Trial

Core Insights - Apogee Therapeutics, Inc. released interim Phase 1 results for APG990, demonstrating a half-life of approximately 60 days, indicating potential for extended dosing intervals [1][5] - The company plans to submit an Investigational New Drug application for APG279, targeting moderate-to-severe atopic dermatitis, with a Phase 1b trial expected to start in 2025 [2] - As of December 31, 2024, the company reported cash and equivalents of $731.1 million, sufficient to fund operations into Q1 2028 [3] Group 1: APG990 Development - APG990 showed a potential best-in-class pharmacokinetic profile with a half-life of approximately 60 days, supporting maintenance dosing every three to six months [5] - The drug was well tolerated across all cohorts, with the most common treatment-emergent adverse event being headache, affecting 53% of participants [5] - No severe adverse events or study discontinuations were reported, and there were no cases of pyrexia or chills [5] Group 2: Future Plans and Financials - The company intends to initiate a Phase 1b clinical trial for APG279 against Dupixent in 2025, with data anticipated in the second half of 2026 [2] - Apogee's financial position is strong, with sufficient cash reserves to support operations until early 2028 [3] - Following the release of positive data, APGE stock increased by 7.14% to $33.68 [3]